2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 357

Osteoporosis and Breast Cancer: Outcomes at a Specialized Osteoporosis Clinic Following a Structured Assessment
Abstract Number: 358

Increased Infection Risk with Concomitant Use of RANK Ligand-Inhibitor, Denosumab and TNF-Inhibitors or Other Biologics: Reality or Illusion? Long Term Experience at the University of Southern California
Abstract Number: 359

The Association of Scheuermann’s Disease with Osteoporotic Vertebral Fracture Risk
Abstract Number: 360

Osteoporosis Prevalence in Lung Transplant Patients
Abstract Number: 361

The Effect of Immunosuppressive and Antiresorptive Therapy on Bone Mineral Density in Lung Transplant Patients
Abstract Number: 362

Evaluation of Osteoporosis Risk Factors in Lung Transplant Patients
Abstract Number: 363

An Examination of Patient Knowledge and Education in Patients with Osteoporosis, Osteopenia and Normal Bone Mineral Density
Abstract Number: 364

Serum Sclerostin Levels in Rheumatoid Arthritis (RA) and Its Correlation with Disease Activity and Bone Mineral Density
Abstract Number: 365

Osteonecrosis of the Femoral Head Is Associated with Low Bone Mass.
Abstract Number: 366

Peripheral Osteoclastogensis Is Coming Back Along with Inflammation Twelve Months after Rituximab Therapy
Abstract Number: 367

Microarray Analyses of Dorsal Root Ganglia for the Study of Pathways Contributing to Pain in Experimental Osteoarthritis
Abstract Number: 368

A Systematic Review of Chronic Pain Assessments with Children and Young People: Exploring Administrative, Scoring and Classification Issues
Abstract Number: 369

Opioid Prescriptions and Adverse Reactions in Children and Adolescents without Serious Diseases
Abstract Number: 370

Relationship Between Alcohol Consumption and Symptom Severity in Chronic Pain Patients
Abstract Number: 371

Chronic Pain in Children Seen at a Rheumatology Clinic: Healthcare Utilization Patterns

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].